6919 — Caliway Biopharmaceuticals Co Balance Sheet
0.000.00%
- TWD251.25bn
- TWD241.85bn
- TWD44.43m
Annual balance sheet for Caliway Biopharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 93.6 | 595 | 1,111 | 3,712 | 9,669 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 3.12 | 7.89 | 5.18 | 
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 111 | 605 | 1,132 | 3,744 | 9,706 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 115 | 106 | 99.6 | 80.4 | 61.3 | 
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 227 | 713 | 1,233 | 3,827 | 9,771 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 64.5 | 39.7 | 48.4 | 73.7 | 52.7 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 180 | 68.2 | 68.8 | 85.6 | 73.7 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 46.6 | 645 | 1,164 | 3,741 | 9,697 | 
| Total Liabilities & Shareholders' Equity | 227 | 713 | 1,233 | 3,827 | 9,771 | 
| Total Common Shares Outstanding |